{"Clinical Trial ID": "NCT00334802", "Intervention": ["INTERVENTION 1:", "Level 1 dose", "Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles", "INTERVENTION 2:", "Level 2 dose", "Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"], "Eligibility": ["Incorporation criteria:", "Histologically and/or cytologically confirmed breast cancer", "Has received adjuvant/neoadjuvant chemotherapy for breast cancer with anthracycline", "Have at least one measurable region", "Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1", "To have an adequate function of the organ (bone marrow, liver and kidney function)", "- Exclusion criteria:", "To have pore pneumonia or pulmonary fibrosis", "To have inflammatory breast cancer", "Within 28 days of the last chemotherapy or radiotherapy, 14 days after the last hormone/immunotherapy or 7 days after the surgery", "\u2022 Have brain metastases with symptoms", "\u2022 have severe complication (heart infarction, infection, drug hypersensitivity or diabetes)"], "Results": ["Performance measures:", "Response of tumours", "The best response recorded from the start of treatment to progression or recurrence of disease using the solid tumour response assessment criteria (RECIST) defines when participants improve (\"response\"), remain the same (\"stable\") or worsen (\" progression\") during treatment.", "Time frame: basis for measuring progressive disease", "Results 1:", "Title of arm/group: Dose Level 1", "Description of the arm/group: Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial reply: 3", "Stable disease: 1", "Progressive diseases: 1", "Non-evaluable: 1", "Results 2:", "Title of arm/group: Dose Level 2", "Description of the arm/group: Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles", "Total number of participants analysed: 56", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial reply: 25", "\u2022 Stable disease: 17", "Progressive diseases: 11", "Non-evaluable: 3"], "Adverse Events": ["Undesirable Events 1:", "Total: 1", "Pneumonia 0/6 (0.00 %)", "Haemoglobin decrease 1/6 (16.67%)", "Anorexia 0/6 (0.00 %)", "- Panic disorder 0/6 (0.00 %)", "Adverse Events 2:", "Total: 3", "Pneumonia 1/56 (1.79%)", "- Haemoglobin decrease 0/56 (0.00 %)", "Anorexia 1/56 (1.79 %)", "- Panic disorder 1/56 (1.79 per cent)"]}